JP2014532704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532704A5 JP2014532704A5 JP2014540046A JP2014540046A JP2014532704A5 JP 2014532704 A5 JP2014532704 A5 JP 2014532704A5 JP 2014540046 A JP2014540046 A JP 2014540046A JP 2014540046 A JP2014540046 A JP 2014540046A JP 2014532704 A5 JP2014532704 A5 JP 2014532704A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- azacytidine
- administering
- pharmaceutical composition
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 33
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 33
- 229960002756 azacitidine Drugs 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 239000003814 drug Substances 0.000 claims 22
- 229940124597 therapeutic agent Drugs 0.000 claims 22
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 190000008236 carboplatin Chemical group 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161554344P | 2011-11-01 | 2011-11-01 | |
| US61/554,344 | 2011-11-01 | ||
| PCT/US2012/062845 WO2013067043A1 (en) | 2011-11-01 | 2012-10-31 | Methods for treating cancers using oral formulations of cytidine analogs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014532704A JP2014532704A (ja) | 2014-12-08 |
| JP2014532704A5 true JP2014532704A5 (OSRAM) | 2015-12-03 |
| JP6162709B2 JP6162709B2 (ja) | 2017-07-12 |
Family
ID=47146759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540046A Active JP6162709B2 (ja) | 2011-11-01 | 2012-10-31 | シチジンアナログの経口製剤を使用して癌を治療する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9125884B2 (OSRAM) |
| EP (1) | EP2773322A1 (OSRAM) |
| JP (1) | JP6162709B2 (OSRAM) |
| KR (1) | KR20140088603A (OSRAM) |
| CN (1) | CN104168884A (OSRAM) |
| AU (1) | AU2012318239B2 (OSRAM) |
| BR (1) | BR112014010417A2 (OSRAM) |
| CA (1) | CA2853949A1 (OSRAM) |
| EA (1) | EA201490911A1 (OSRAM) |
| HK (1) | HK1200716A1 (OSRAM) |
| IL (1) | IL232268A0 (OSRAM) |
| MX (1) | MX2014005314A (OSRAM) |
| PH (1) | PH12014500965A1 (OSRAM) |
| SG (1) | SG11201401946QA (OSRAM) |
| TW (2) | TWI558401B (OSRAM) |
| WO (1) | WO2013067043A1 (OSRAM) |
| ZA (2) | ZA201403106B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2695609B1 (en) | 2008-05-15 | 2019-12-11 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| BR112014010699B1 (pt) | 2011-11-03 | 2020-12-15 | Millennium Pharmaceuticals, Inc | Uso de um inibidor nae com um agente de hipometilação para tratar malignidade hematológica e kit |
| WO2015107105A1 (en) * | 2014-01-15 | 2015-07-23 | Apogenix Gmbh | Method of predicting the responsiveness of a cancer disease to treatment on the basis of DNA methylation |
| WO2015195634A1 (en) * | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| WO2015195786A2 (en) * | 2014-06-17 | 2015-12-23 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
| CN104147036B (zh) * | 2014-08-24 | 2017-04-05 | 浙江大学 | 地西他滨和奥沙利铂在制备治疗肾细胞癌组合药物中应用 |
| TWI716415B (zh) * | 2015-06-29 | 2021-01-21 | 日商大賽璐股份有限公司 | 易服用性固態製劑之製造方法及易服用性固態製劑 |
| TWI690333B (zh) | 2015-06-29 | 2020-04-11 | 日商大賽璐股份有限公司 | 易服用性固態製劑（有核錠）之製造方法及易服用性固態製劑 |
| WO2017037022A1 (en) * | 2015-09-01 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Compounds and methods useful for treating or preventing hematological cancers |
| US11027021B2 (en) | 2016-03-15 | 2021-06-08 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors |
| EP3442591A4 (en) * | 2016-04-15 | 2019-11-20 | Seattle Genetics, Inc. | COMBINATIONS OF CD33 ANTIBODY-ACTIVE CONJUGATES WITH HYPOMETHYLATING AGENTS |
| EP3463463A4 (en) | 2016-06-03 | 2020-01-15 | Seattle Genetics, Inc. | Combination of cd33 antibody drug conjugates with chemotherapeutic agents |
| KR20190015300A (ko) * | 2016-06-06 | 2019-02-13 | 셀진 코포레이션 | 2-(4-클로로페닐)-n-((2-(2,6-다이옥소피페리딘-3-일)-1-옥소아이소인돌린-5-일)메틸)-2,2-다이플루오로아세트아마이드에 의한 혈액 악성종양의 치료 |
| US11191771B2 (en) | 2016-06-09 | 2021-12-07 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors |
| EP3481953A4 (en) | 2016-07-06 | 2020-04-15 | Youhealth Biotech, Limited | SPECIFIC METHYLATION MARKERS OF LIVER CANCER AND USES THEREOF |
| AU2018248423A1 (en) * | 2017-04-04 | 2019-10-17 | Loma Linda University | Biologic for the treatment of cancer |
| GB201819453D0 (en) * | 2018-11-29 | 2019-01-16 | Ucl Business Plc | Molecular signature |
| JP7767279B2 (ja) | 2019-11-04 | 2025-11-11 | ジェロン・コーポレーション | 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用 |
| WO2023140691A1 (ko) * | 2022-01-21 | 2023-07-27 | 주식회사 피노바이오 | 5-아자-4'-티오-2'-데옥시사이티딘을 함유하는 경구용 제형 및 이의 제조방법 |
| WO2024191252A1 (ko) * | 2023-03-14 | 2024-09-19 | 주식회사 피노바이오 | 골수에 작용하는 5-아자-4'-티오-2'-데옥시사이티딘의 최고 혈중농도를 정교하게 제어가능한 경구용 제형 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| ATE302597T1 (de) | 1997-06-06 | 2005-09-15 | Depomed Inc | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
| MXPA02007254A (es) | 2000-02-04 | 2002-12-09 | Depomed Inc | Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero. |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| AU2003286836A1 (en) | 2002-10-31 | 2004-06-07 | Supergen, Inc. | Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
| US20060069060A1 (en) * | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE038768T2 (hu) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
| PT1931321T (pt) | 2005-08-31 | 2019-05-14 | Abraxis Bioscience Llc | Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos |
| CA2620389C (en) | 2005-08-31 | 2014-06-17 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US20080057086A1 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| ES2700074T3 (es) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
| US20080182806A1 (en) | 2007-01-25 | 2008-07-31 | Nevada Cancer Institute | Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents |
| BRPI0817269A2 (pt) | 2007-09-26 | 2014-10-07 | Sinai School Medicine | Análogos de azacitidina e usos dos mesmos |
| CA2742252A1 (en) | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| RU2010145529A (ru) | 2008-04-10 | 2012-05-20 | АБРАКСИС БАЙОСАЙЕНС ЭлЭлСи (US) | Композиции гидрофобных производных таксана и их применение |
| WO2009126401A1 (en) | 2008-04-10 | 2009-10-15 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| EP2695609B1 (en) | 2008-05-15 | 2019-12-11 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| US20100143351A1 (en) * | 2008-11-22 | 2010-06-10 | Genentech, Inc. | Anti-Angiogenesis Therapy for the Treatment of Breast Cancer |
| US8492361B2 (en) | 2009-02-10 | 2013-07-23 | Celgene Corporation | Methods for treating non-small cell lung cancer using 5-azacytidine |
| JP6031437B2 (ja) | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス， エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
| WO2013022872A1 (en) | 2011-08-10 | 2013-02-14 | Celgene Corporation | Gene methylation biomarkers and methods of use thereof |
-
2012
- 2012-10-31 EA EA201490911A patent/EA201490911A1/ru unknown
- 2012-10-31 BR BRBR112014010417-4A patent/BR112014010417A2/pt not_active Application Discontinuation
- 2012-10-31 HK HK15101233.8A patent/HK1200716A1/xx unknown
- 2012-10-31 SG SG11201401946QA patent/SG11201401946QA/en unknown
- 2012-10-31 KR KR1020147014861A patent/KR20140088603A/ko not_active Withdrawn
- 2012-10-31 US US13/665,778 patent/US9125884B2/en not_active Expired - Fee Related
- 2012-10-31 MX MX2014005314A patent/MX2014005314A/es not_active Application Discontinuation
- 2012-10-31 CN CN201280065749.3A patent/CN104168884A/zh active Pending
- 2012-10-31 TW TW101140377A patent/TWI558401B/zh not_active IP Right Cessation
- 2012-10-31 EP EP12783817.5A patent/EP2773322A1/en not_active Withdrawn
- 2012-10-31 AU AU2012318239A patent/AU2012318239B2/en not_active Ceased
- 2012-10-31 JP JP2014540046A patent/JP6162709B2/ja active Active
- 2012-10-31 CA CA2853949A patent/CA2853949A1/en not_active Withdrawn
- 2012-10-31 PH PH1/2014/500965A patent/PH12014500965A1/en unknown
- 2012-10-31 TW TW105130025A patent/TW201700103A/zh unknown
- 2012-10-31 WO PCT/US2012/062845 patent/WO2013067043A1/en not_active Ceased
-
2014
- 2014-04-27 IL IL232268A patent/IL232268A0/en unknown
- 2014-04-29 ZA ZA2014/03106A patent/ZA201403106B/en unknown
-
2015
- 2015-04-16 US US14/688,623 patent/US9693987B2/en active Active
- 2015-04-28 ZA ZA2015/02909A patent/ZA201502909B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532704A5 (OSRAM) | ||
| JP2011068653A5 (OSRAM) | ||
| JP2016528162A5 (OSRAM) | ||
| JP2006515883A5 (OSRAM) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| JP2013527232A5 (OSRAM) | ||
| JP2014040437A5 (OSRAM) | ||
| JP2012521435A5 (OSRAM) | ||
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| HK1200716A1 (zh) | 使用胞苷類似物的口服製劑治療癌症的方法 | |
| JP2009545600A5 (OSRAM) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2014524469A5 (OSRAM) | ||
| RU2013154355A (ru) | Способ лечения мезотелиомы ингибитором рi3к | |
| JP2015537009A5 (OSRAM) | ||
| JP2014507475A5 (OSRAM) | ||
| JP2015507020A5 (OSRAM) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP2013540734A5 (OSRAM) | ||
| JP2020520385A5 (OSRAM) | ||
| RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
| IL292725A (en) | Benzazepines are combined for the treatment of Tourette syndrome | |
| JP2011513315A5 (OSRAM) | ||
| TW201513870A (zh) | 含伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| Xingsheng et al. | Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer |